TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32941098
Drug: Placebo; at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo; at least one placebo administered to participants.
Study: 32549100
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine group (10% lidocaine oropharyngeal spray, five minutes before laryngoscopy and endotracheal intubation)
Study: 32549100
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no lidocaine spray)
Study: 33197226
Drug: Continued chemotherapy
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued chemotherapy
Study: 33216632
Drug: Korean Red
Normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Korean Red Ginseng (3 g per day for 12 weeks)
Study: 36297060
Drug: Ketone monoester
Normalized name: Ketonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketone monoester supplement (KME) 25 g
Study: 37365597
Drug: neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: neoadjuvant chemotherapy (nCT)
Study: 34750146
Drug: 81 mg
Normalized name: aspirin 81 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 81 mg ASA
Study: 34750146
Drug: 325 mg
Normalized name: lysine 325 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325 mg ASA
Study: 36018753
Drug: Dendritic cell
Normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dendritic cell vaccines with 0.10, 0.33, or 1.0 µg of recombinant SARS-CoV-2 spike protein, with or without GM-CSF
Study: 36018753
Drug: Dendritic cell
Normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dendritic cell vaccines without GM-CSF
Study: 34219257
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and vitamin D1–25 supplementation for high-risk patients, routine daily calcium samples until 48 hours post-surgery.
Study: 34219257
Drug: Routine daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine daily calcium samples for low-risk patients until 48 hours post-surgery.
Study: 33560442
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy with rituximab
Study: 32371123
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy without rituximab (Control)
Study: 34705999
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no light treatment)
Study: 35671553
Drug: Very Low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very Low Nicotine Content (VLNC) cigarettes (0.4 mg/g nicotine)
Study: 35671553
Drug: Normal Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Normal Nicotine Content (NNC) cigarettes (15.8 mg nicotine/g tobacco)
Study: 36471412
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of NIKA and EMDR
Study: 33036645
Drug: Breast milk
Normalized name: BREAST MILK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast milk oral stimulation
Study: 33036645
Drug: Physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline oral stimulation
Study: 34166587
Drug: DR/ER-MPH (Delayed-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: DR/ER-MPH (Delayed-release and extended-release methylphenidate)
Study: 33290616
Drug: PF-06826647 (doses:
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06826647 (doses: 3, 10, 30, 100, 200, 400, or 1,600 mg for SAD; 30, 100, 400, or 1,200 mg q.d. or 200 mg b.i.d. for 10 days for MAD)
Study: 35440611
Drug: Paracetamol (Control)
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol (Control)
Study: 32380069
Drug: Azithromycin 250
Normalized name: azithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 250 mg or 500 mg, three times a week for 6 months
Study: 34738518
Drug: 7-day amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7-day amoxicillin treatment
Study: 34738518
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose (35-50 mg/kg/day)
Study: 34738518
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose (70-90 mg/kg/day)
Study: 34228547
Drug: 7-day treatment
Normalized name: Gyne-Lotrimin 1% 7-Day Treatment Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day treatment
Study: 34726708
Drug: 3-day treatment
Normalized name: Gyne-Lotrimin 2% 3-Day Treatment Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day treatment
Study: 34738518
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses and durations
Study: 32962487
Drug: Ranibizumab plus
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab plus fufang xueshuantong capsule (cFXST)
Study: 34535610
Drug: Topical clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical clindamycin 1% solution combined with LAight® therapy (8 bi-weekly treatments)
Study: 34535610
Drug: Topical clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical clindamycin 1% solution only
Study: 33802651
Drug: Ketogenic Diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketogenic Diet with Ketone Supplement (KD + KS)
Study: 34416788
Drug: Focal laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focal laser therapy (micropulse laser or argon laser coagulation) for treating leakage points visible in fluorescein angiography (FA)
Study: 34416788
Drug: Systemic administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic administration of mineralocorticoid receptor antagonists, carbonic anhydrase inhibitors, or non-steroidal anti-inflammatory drugs
Study: 33207606
Drug: Beetroot powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot powder providing 200 mg nitrate
Study: 33207606
Drug: Beetroot with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot with 0.8 g of L-arginine
Study: 33207606
Drug: Beetroot with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot with 1.5 g of L-arginine
Study: 33207606
Drug: Beetroot with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot with 3.0 g of L-arginine
Study: 34587703
Drug: Preload of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preload of low-intensity-cooked yam paste (10 g) before rice meal
Study: 33591858
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (20/10/3 g)
Study: 33591858
Drug: Placebo (30/3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (30/3 g)
Study: 35085715
Drug: Inverse-planned intensity
Normalized name: Inversedine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inverse-planned intensity modulated radiation therapy
Study: 35085715
Drug: Forward-planned intensity
Normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Forward-planned intensity modulated radiation therapy
Study: 35234673
Drug: Nesvacumab 3
Normalized name: Nesvacumab
DrugBank: Nesvacumab (DB15330)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nesvacumab 3 mg + aflibercept 2 mg (LD combo)
Study: 35234673
Drug: Nesvacumab 6
Normalized name: Nesvacumab
DrugBank: Nesvacumab (DB15330)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nesvacumab 6 mg + aflibercept 2 mg (HD combo)
Study: 35234673
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injection (IAI) 2 mg
Study: 33197396
Drug: Standard ACLS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ACLS treatment
Study: 33878461
Drug: Interferon α‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon α‐2b spray
Study: 35010877
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cocoa and red berries
Study: 35878179
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (placebo control group)
Study: 32668833
Drug: Interscalene brachial
Normalized name: Brachiara mutica pollen
DrugBank: Urochloa mutica pollen (DB10716)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interscalene brachial plexus block (ISB) with 15 ml of 0.5% ropivacaine
Study: 32668833
Drug: Anterior suprascapular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterior suprascapular nerve block (SSB) with 15 ml of 0.5% ropivacaine
Study: 32668833
Drug: Posterior suprascapular
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior suprascapular nerve block (SSB) with 15 ml of 0.5% ropivacaine
Study: 33693907
Drug: Testosterone treatment
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone treatment (injectable testosterone undecanoate)
Study: 36027670
Drug: Femistina (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femistina (40 mg, oral, twice daily for 20 days)
Study: 36027670
Drug: Canephron (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canephron (3 × 5 ml taken orally three times daily for 4 weeks)
Study: 34022636
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose of 4-factor prothrombin complex concentrate (4FPCC) at 1500 IU
Study: 34022636
Drug: Variable dosing
Normalized name: methohexital
DrugBank: Methohexital (DB00474)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Variable dosing of 4-factor prothrombin complex concentrate (4FPCC)
Study: 34404144
Drug: Micro-implant assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro-implant assisted rapid palatal expansion (MARPE) in fusion group
Study: 34404144
Drug: Micro-implant assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro-implant assisted rapid palatal expansion (MARPE) in non-fusion group
Study: 34285004
Drug: Antibiotics (penicillins,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (penicillins, cephalosporins, macrolides)
Study: 32916306
Drug: Oral butyrate
Normalized name: butyrate
DrugBank: Butyric Acid (DB03568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral butyrate supplementation
Study: 36259475
Drug: MitoQ (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: MitoQ (20 mg/day, oral)
Study: 32920164
Drug: CBT-based mobile
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT-based mobile application (4 min daily exercises for two weeks)
Study: 36174627
Drug: Adjuvant S-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant S-1 plus endocrine therapy
Study: 34813901
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement (20 g whey protein + 800 IU vitamin D)
Study: 33735416
Drug: Varenicline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (1 mg BID for 12 weeks)
Study: 33423990
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy (ESWT) applied for 5 weeks, one session per week
Study: 33423990
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) applied with 15 sessions on consecutive days
Study: 34532888
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg/day
Study: 35976021
Drug: Tapinarof 1%
Normalized name: TAPINAROF 1% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapinarof 1% cream applied once daily for 12 weeks
Study: 33498159
Drug: Aggressive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive treatment at both metastatic and primary sites (Group A)
Study: 33498159
Drug: Non-aggressive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-aggressive treatment (Group B)
Study: 33498159
Drug: Patients not
Normalized name: Lamictal 25mg-100mg Tablet Starter Kit (For Patients Not Taking Enzyme-Inducing Drugs or Valproate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients not treated with PD-L1 inhibitors
Study: 35266589
Drug: TXA 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA 15 mg/kg bolus dose, followed by 2 mg/kg/hr infusion over 8 hours
Study: 35266589
Drug: TXA 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA 30 mg/kg bolus dose, followed by 4 mg/kg/hr infusion over 8 hours
Study: 35266589
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline placebo bolus and infusion
Study: 34040108
Drug: JNJ-61803534 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-61803534 (oral formulation)
Study: 32009005
Drug: Trigger point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trigger point injections
Study: 35954850
Drug: Psychodynamic psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychodynamic psychotherapy treatment over 28 sessions
Study: 33904295
Drug: Short course
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short course antibiotics (1g of ceftriaxone with 500mg of metronidazole stat post umbilical cord clamping)
Study: 33904295
Drug: Long course
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long course antibiotics (post-operative doses of intravenous ceftriaxone 1g 12 hourly with 500mg of metronidazole eight hourly for 24 hours, then oral cefuroxime 500mg twice daily and metronidazole 400mg thrice daily for five days)
Study: 33904295
Drug: Short course
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short course antibiotics
Study: 33904295
Drug: Long course
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long course antibiotics
Study: 32054483
Drug: Wharton's jelly
Normalized name: Human Umbilical Cord Wharton's Jelly-derived Mesenchymal Stem Cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wharton's jelly formulation
Study: 34030555
Drug: BDP 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP 200 µg BID
Study: 34030555
Drug: BDP 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP 50 µg BID
Study: 34030555
Drug: BDP 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP 400 µg BID
Study: 34030555
Drug: QVAR® 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: QVAR® 160 µg BID
Study: 33634478
Drug: Reduced-dose facilitated
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced-dose facilitated PCI strategy (reduced-dose fibrinolysis combined with simultaneous transfer for immediate invasive therapy with a time interval between fibrinolysis to PCI < 3 hours)
Study: 33634478
Drug: Standard pharmacoinvasive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pharmacoinvasive treatment
Study: 37057581
Drug: Chamomile vaginal
Normalized name: Chamomile
DrugBank: Chamomile (DB14357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chamomile vaginal gel 5%
Study: 37057581
Drug: Placebo vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo vaginal gel
Study: 34032739
Drug: On-demand treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand treatment with nonacog alfa
Study: 34032739
Drug: Prophylactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic treatment with nonacog alfa
Study: 32583300
Drug: Aprepitant and
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant and transdermal scopolamine preoperatively followed by ondansetron and dexamethasone intraoperatively, with total intravenous anesthesia.
Study: 32583300
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (aprepitant and transdermal scopolamine)
Study: 33216048
Drug: Grape vinegar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape vinegar and rose water solution
Study: 32227432
Drug: Empagliflozin 10
Normalized name: empagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 10 or 25 mg
Study: 33050893
Drug: Theory of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theory of planned behavior (TPB) based oral health education consisting of four one-hour training sessions over 1 week.
Study: 36717556
Drug: Levonorgestrel implant
Normalized name: levonorgestrel IMPLANT KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel implant (LNG)
Study: 34801714
Drug: Tafenoquine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafenoquine 200 mg weekly
Study: 34097713
Drug: 0.75 mg
Normalized name: propinox 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg ml‐1 S‐ketamine in oxycodone PCA
Study: 34097713
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg ml‐1 S‐ketamine in oxycodone PCA
Study: 34097713
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg ml‐1 S‐ketamine in oxycodone PCA
Study: 33731164
Drug: Vancomycin (powder,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (powder, 1 g) applied before water-tight closure of the joint capsule
Study: 33067287
Drug: Stand-alone VR
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stand-alone VR (6-week, internet-based intervention with weekly online sessions and daily exercises)
Study: 35830423
Drug: ZeroPhobia: Arachnophobia,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZeroPhobia: Arachnophobia, a 6‐week Augmented Reality Exposure Therapy smartphone self‐help application
Study: 35012962
Drug: Plitidepsin 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plitidepsin 1.5 mg once daily for 3 days
Study: 35012962
Drug: Plitidepsin 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plitidepsin 2.0 mg once daily for 3 days
Study: 35012962
Drug: Plitidepsin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plitidepsin 2.5 mg once daily for 3 days
Study: 35012962
Drug: Plitidepsin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plitidepsin (all doses)
Study: 32295593
Drug: Indacaterol/glycopyrronium/mometasone furoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol/glycopyrronium/mometasone furoate (IND/GLY/MF) high-dose ICS (160 μg mometasone furoate)
Study: 32295593
Drug: Indacaterol/glycopyrronium/mometasone furoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol/glycopyrronium/mometasone furoate (IND/GLY/MF) medium-dose ICS (80 μg mometasone furoate)
Study: 32295593
Drug: Salmeterol/fluticasone propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/fluticasone propionate (SFC) high-dose ICS (50/500 μg)
Study: 32295593
Drug: Indacaterol/glycopyrronium/mometasone furoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol/glycopyrronium/mometasone furoate (IND/GLY/MF) high-dose ICS
Study: 32295593
Drug: Indacaterol/glycopyrronium/mometasone furoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol/glycopyrronium/mometasone furoate (IND/GLY/MF) medium-dose ICS
Study: 34469767
Drug: Quadpill treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadpill treatment (irbesartan 37.5 mg, amlodipine 1.25 mg, indapamide 0.625 mg, bisoprolol 2.5 mg)
Study: 34469767
Drug: Quadpill treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadpill treatment
Study: 34469767
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose monotherapy (irbesartan 150 mg)
Study: 36116516
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose monotherapy
Study: 32362238
Drug: High-intensity intervention
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity intervention (Motivational interviewing, dietary advice on prescription, grocery store lecture, website, weekly e-mails)
Study: 35532889
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg testosterone enanthate weekly (n=24)
Study: 33545945
Drug: Pestle needle
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pestle needle therapy applied to acupoints (bilateral Shao ze, bilateral Ru gen, Dan zhong, 8 array acupoints of Shen dao) once a day for 5 days
Study: 34563412
Drug: Neonatal circumcision
Normalized name: Foreskin fibroblast (neonatal)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neonatal circumcision + antibiotic prophylaxis (CATB)
Study: 34563412
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis alone (ATB)
Study: 33804374
Drug: Traditional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional physical therapy for 30 min, three times a week for four weeks
Study: 36288583
Drug: US-guided Erector
Approvals — FDA: no, EMA: no, PMDA: no
Description: US-guided Erector Spinae Block (ESB) with 25 mg bupivacaine 0.5% plus 8 mg dexamethasone (10 mL volume)
Study: 36288583
Drug: US-guided Thoracic
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: US-guided Thoracic Paravertebral Block (PVB) with 25 mg bupivacaine 0.5% plus 8 mg dexamethasone (10 mL volume)
Study: 33465277
Drug: PF-06372865 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06372865 (25 mg twice daily for 14 days after titration for 7 days)
Study: 33465277
Drug: PF-06372865 (42.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06372865 (42.5 mg twice daily for 14 days after titration for 7 days)
Study: 35436355
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose melatonin (5.0 mg)
Study: 35436355
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose melatonin (0.3 mg)